XNCRXencor, Inc.Finished
XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
Metastatic Castration-Resistant Prostate Cancer
10Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due Jun 2025, none posted yet
Counts until it's fixed
Worry score10
Score over time
- Stage
- Phase 2
- Patients
- 72 (final count)
- Started
- Oct 22, 2021
- Main results expected
- Jun 10, 2025
- Fully finished
- Jun 10, 2025
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Incidence of treatment-emergent adverse events (safety and tolerability of vudalimab)
Measured over: 8 weeks
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2025-06-10, no fading
Raw record changes
- none yet
Trial ID NCT05005728 · record last updated 2026-05-05 · checked 2026-11-09 15:47 UTC